Download PDF
Endoscopy 2004; 36(2): 130-136
DOI: 10.1055/s-2004-814180
State of the Art Review
© Georg Thieme Verlag Stuttgart · New York

Inflammatory Bowel Disease: What is New?

P.  Marteau1 , F.  Daniel1 , P.  Seksik1 , R.  Jian1
  • 1Dept. of Gastroenterology, Georges Pompidou European Hospital, Paris, and University of Paris V, France
Further Information

Publication History

Publication Date:
06 February 2004 (online)

Also available at
    Permissions and Reprints

This article reviews a selection of 50 papers on inflammatory bowel disease published between April 2002 and August 2003. The new information and progress summarized here includes: the role of bacteria, their interaction with CARD15/NOD2 gene products and the modulating effects of probiotics; new imaging techniques, such as wireless capsule endoscopy and chromoendoscopy for detecting dysplasia, and fecal markers. It has not been possible to review every aspect of treatment, and the focus here is on factors capable of predicting the efficacy and tolerance of infliximab and new treatments, including natalizumab, thalidomide, cyclophosphamide and 6-thioguanine.

References

  • 1 Bonen D K, Ogura Y, Nicolae D L. et al . Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan.  Gastroenterology. 2003;  124 140-146
    CrossrefPubMedGoogle Scholar
  • 2 Inohara N, Ogura Y, Fontalba A. et al . Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn’s disease.  J Biol Chem. 2003;  278 5509-5512
    CrossrefPubMedGoogle Scholar
  • 3 Lala S, Ogura Y, Osborne C. et al . Crohn’s disease and the NOD2 gene: a role for Paneth cells.  Gastroenterology. 2003;  125 47-57
    CrossrefPubMedGoogle Scholar
  • 4 Fellermann K, Wehkamp J, Herrlinger K R, Stange E F. Crohn’s disease: a defensin deficiency syndrome?.  Eur J Gastroenterol Hepatol. 2003;  15 627-634
    PubMedGoogle Scholar
  • 5 Seksik P, Rigottier-Gois L, Gramet G. et al . Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon.  Gut. 2003;  52 237-242
    CrossrefPubMedGoogle Scholar
  • 6 Borruel N, Casellas F, Antolin M. et al . Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa.  Am J Gastroenterol. 2003;  98 865-870
    CrossrefPubMedGoogle Scholar
  • 7 Gionchetti P, Rizzello F, Helwig U. et al . Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.  Gastroenterology. 2003;  124 1202-1209
    CrossrefPubMedGoogle Scholar
  • 8 Prantera C, Scribano M L, Falasco G. et al . Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG.  Gut. 2002;  51 405-409
    CrossrefPubMedGoogle Scholar
  • 9 Borody T J, Warren E F, Leis S. et al . Treatment of ulcerative colitis using fecal bacteriotherapy.  J Clin Gastroenterol. 2003;  37 42-47
    CrossrefPubMedGoogle Scholar
  • 10 Cosnes J, Carbonnel F, Beaugerie L. et al . Effects of appendicectomy on the course of ulcerative colitis.  Gut. 2002;  51 803-807
    CrossrefPubMedGoogle Scholar
  • 11 Jess T, Winther K V, Munkholm P. et al . Mortality and causes of death in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark.  Gastroenterology. 2002;  122 1808-1814
    CrossrefPubMedGoogle Scholar
  • 12 Ludeman L, Shepherd N A. What is diverticular colitis?.  Pathology. 2002;  34 568-572
    CrossrefPubMedGoogle Scholar
  • 13 Spiller R C. Postinfectious irritable bowel syndrome.  Gastroenterology. 2003;  124 1662-1671
    CrossrefPubMedGoogle Scholar
  • 14 Nahon S, Bouhnik Y, Lavergne-Slove A. et al . Colonoscopy accurately predicts the anatomical severity of colonic Crohn’s disease attacks: correlation with findings from colectomy specimens.  Am J Gastroenterol. 2002;  97 3102-3107
    CrossrefPubMedGoogle Scholar
  • 15 Brooker J C, Beckett C G, Saunders B P, Benson M J. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn’s strictures may improve the outcome: a retrospective case series.  Endoscopy. 2003;  35 333-337
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Herrerias J M, Caunedo A, Rodriguez-Tellez M. et al . Capsule endoscopy in patients with suspected Crohn’s disease and negative endoscopy.  Endoscopy. 2003;  35 564-568
    Google Scholar
  • 17 Eliakim R, Fischer D, Suissa A. et al . Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium follow-through and computerized tomography in patients with suspected Crohn’s disease.  Eur J Gastroenterol Hepatol. 2003;  15 363-367
    Google Scholar
  • 18 Messmann H, Endlicher E, Freunek G. et al . Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation.  Gut. 2003;  52 1003-1007
    CrossrefPubMedGoogle Scholar
  • 19 Kiesslich R, Fritsch J, Holtmann M. et al . Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.  Gastroenterology. 2003;  124 880-888
    CrossrefPubMedGoogle Scholar
  • 20 Chen R, Rabinovitch P S, Crispin D A. et al . DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free.  Am J Pathol. 2003;  162 665-672
    PubMedGoogle Scholar
  • 21 Stahlberg D, Veress B, Tribukait B, Broome U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study.  Dis Colon Rectum. 2003;  46 770-778
    CrossrefPubMedGoogle Scholar
  • 22 Bernstein C N, Eaden J, Steinhart A H. et al . Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.  Inflamm Bowel Dis. 2002;  8 356-361
    PubMedGoogle Scholar
  • 23 Pardi D S, Loftus E V Jr, Kremers W K. et al . Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.  Gastroenterology. 2003;  124 889-893
    CrossrefPubMedGoogle Scholar
  • 24 Laghi A, Borrelli O, Paolantonio P. et al . Contrast enhanced magnetic resonance imaging of the terminal ileum in children with Crohn’s disease.  Gut. 2003;  52 393-397
    CrossrefPubMedGoogle Scholar
  • 25 Neurath M F, Vehling D, Schunk K. et al . Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies.  Am J Gastroenterol. 2002;  97 1978-1985
    CrossrefPubMedGoogle Scholar
  • 26 Van Assche G, Vanbeckevoort D, Bielen D. et al . Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease.  Am J Gastroenterol. 2003;  98 332-339
    PubMedGoogle Scholar
  • 27 Lee S S, Ha H K, Yang S K. et al . CT of prominent pericolic or perienteric vasculature in patients with Crohn’s disease: correlation with clinical disease activity and findings on barium studies.  AJR Am J Roentgenol. 2002;  179 1029-1036
    PubMedGoogle Scholar
  • 28 Kane S V, Sandborn W J, Rufo P A. et al . Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.  Am J Gastroenterol. 2003;  98 1309-1314
    CrossrefPubMedGoogle Scholar
  • 29 Thjodleifsson B, Sigthorsson G, Cariglia N. et al . Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives?.  Gastroenterology. 2003;  124 1728-1737
    CrossrefPubMedGoogle Scholar
  • 30 Loftus E V Jr, Crowson C S, Sandborn W J. et al . Long-term fracture risk in patients with Crohn’s disease: a population-based study in Olmsted County, Minnesota.  Gastroenterology. 2002;  123 468-475
    CrossrefPubMedGoogle Scholar
  • 31 Klaus J, Armbrecht G, Steinkamp M. et al . High prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease.  Gut. 2002;  51 654-658
    CrossrefPubMedGoogle Scholar
  • 32 von Tirpitz C, Klaus J, Steinkamp M. et al . Therapy of osteoporosis in patients with Crohn’s disease: a randomized study comparing sodium fluoride and ibandronate.  Aliment Pharmacol Ther. 2003;  17 807-816
    CrossrefPubMedGoogle Scholar
  • 33 De Oca J, Sanchez-Santos R, Rague J M. et al . Long-term results of ileal pouch-anal anastomosis in Crohn’s disease.  Inflamm Bowel Dis. 2003;  9 171-175
    PubMedGoogle Scholar
  • 34 Gramlich T, Delaney C P, Lynch A C. et al . Pathological subgroups may predict complications but not late failure after ileal pouch-anal anastomosis for indeterminate colitis.  Colorectal Dis. 2003;  5 315-319
    CrossrefPubMedGoogle Scholar
  • 35 Rudolph W G, Uthoff S M, McAuliffe T L. et al . Indeterminate colitis: the real story.  Dis Colon Rectum. 2002;  45 1528-1534
    CrossrefPubMedGoogle Scholar
  • 36 Ravid A, Richard C S, Spencer L M. et al . Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis.  Dis Colon Rectum. 2002;  45 1283-1288
    CrossrefPubMedGoogle Scholar
  • 37 Probert C S, Hearing S D, Schreiber S. et al . Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.  Gut. 2003;  52 998-1002
    CrossrefPubMedGoogle Scholar
  • 38 Domenech E, Garcia-Planella E, Bernal I. et al . Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis.  Aliment Pharmacol Ther. 2002;  16 2061-2065
    CrossrefPubMedGoogle Scholar
  • 39 Vernia P, Annese V, Bresci G. et al . Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial.  Eur J Clin Invest. 2003;  33 244-248
    CrossrefPubMedGoogle Scholar
  • 40 Parsi M A, Achkar J P, Richardson S. et al . Predictors of response to infliximab in patients with Crohn’s disease.  Gastroenterology. 2002;  123 707-713
    CrossrefPubMedGoogle Scholar
  • 41 Vermeire S, Louis E, Carbonez A. et al . Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease.  Am J Gastroenterol. 2002;  97 2357-2363
    CrossrefPubMedGoogle Scholar
  • 42 Baert F, Noman M, Vermeire S. et al . Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease.  N Engl J Med. 2003;  348 601-608
    CrossrefPubMedGoogle Scholar
  • 43 Farrell R J, Alsahli M, Jeen Y T. et al . Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial.  Gastroenterology. 2003;  124 917-924
    PubMedGoogle Scholar
  • 44 Kugathasan S, Levy M B, Saeian K. et al . Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction.  Am J Gastroenterol. 2002;  97 1408-1414
    CrossrefPubMedGoogle Scholar
  • 45 Sabate J M, Villarejo J, Lemann M. et al . An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn’s disease.  Aliment Pharmacol Ther. 2002;  16 1117-1124
    CrossrefPubMedGoogle Scholar
  • 46 Ghosh S, Goldin E, Gordon F H. et al . Natalizumab for active Crohn’s disease.  N Engl J Med. 2003;  348 24-32
    PubMedGoogle Scholar
  • 47 Caprilli R, Cottone M, Tonelli F. et al . Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn’s disease: a pragmatic, double-blind, randomized controlled trial.  Aliment Pharmacol Ther. 2003;  17 517-523
    CrossrefPubMedGoogle Scholar
  • 48 Stallmach A, Wittig B M, Moser C. et al . Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease.  Gut. 2003;  52 377-382
    CrossrefPubMedGoogle Scholar
  • 49 Bonaz B, Boitard J, Marteau P. et al . Thioguanine in patients with Crohn’s disease intolerant or resistant to azathioprine/mercaptopurine.  Aliment Pharmacol Ther. 2003;  18 401-408
    CrossrefPubMedGoogle Scholar
  • 50 Dubinsky M C, Vasiliauskas E A, Singh H. et al . 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.  Gastroenterology. 2003;  125 298-303
    CrossrefPubMedGoogle Scholar

P. Marteau,M. D., Ph. D. 

Gastroenterology Department · Hôpital Européen Georges Pompidou

20, rue Leblanc 75908 Paris Cedex 15 · France

Fax: +33-1-56 09 35 54

Email: philippe.marteau@hop.egp.ap-hop-paris.fr

      >